Trigeminal neuralgia treated with pregabalin in family medicine settings: Its effect on pain alleviation and cost reduction

Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2009, Pages 582-590

  Pérez, Concepción ^a   Saldaña, María T ^b   Navarro, Ana ^c   Martínez, Silvia ^d   Rejas, Javier ^e  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Primary Care Health Centre Raices   (Spain)

^c Puerta Del Ángel Primary Care Center   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Burden of illness; Cost; Health care resource utilization; Lost workdays equivalents; Pregabalin; Trigeminal neuralgia

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PREGABALIN;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; FAMILY MEDICINE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MULTICENTER STUDY; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SECONDARY ANALYSIS; TRIGEMINUS NEURALGIA; WORKING TIME;

ABSENTEEISM; ANALGESICS; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TRIGEMINAL NEURALGIA;

EID: 65449138272     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009333017     Document Type: Article

References (23)

1. Merskey H, Bogduk N, eds. Classification of Chronic Pain. 2 nd ed. Seattle, Wash: IASP Task Force on Taxonomy (IASP) Press ; 1994.
2. Elias WJ, Burchiel KJ Trigeminal neuralgia and other neuropathic pain syndromes of the head and face. Curr Pain Headache Rep. 2002 ; 6: 115-124.
3. Kitt CA, Gruber K., Davis M., Woolf CJ, Levine JD Trigeminal neuralgia: opportunities for research and treatment. Pain. 2000 ; 85: 3-7. (Pubitemid 30110738)
4. Nurmikko TJ, Eldridge PR Trigeminal neuralgia-pathophysiology, diagnosis and current treatment. Br J Anaesth. 2001 ; 87: 117-132. (Pubitemid 32631681)
5. Rodríguez MJ, García AJ A registry of the aetiology and costs of neuropathic pain in pain clinics: results of the Registry of aEtiologies and Costs (REC) in Neuropathic Pain Disorders Study. Clin Drug Invest. 2007 ; 27: 771-782. (Pubitemid 47529293)
6. Berger A., Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004 ; 5: 143-149. (Pubitemid 38879392)
7. Tölle T., Dukes E., Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract. 2006 ; 6: 153-160. (Pubitemid 44193941)
8. Sindrup SH, Jensen TS Pharmacotherapy of trigeminal neuralgia. Clin J Pain. 2002 ; 18: 22-27. (Pubitemid 34118962)
9. Clinical Knowledge Summaries. Trigeminal neuralgia. http://cks.library. nhs.uk/trigeminal-neuralgia/view-whole-guidance. Issued July 2005; accessed December 10, 2007.
10. Gilron I., Watson CP, Cahill CM, Moulin DE Neuropathic pain: a practical guide for the clinician. CMAJ. 2006 ; 175: 265-275. (Pubitemid 44230827)
11. Jorns TP, Zakrzewska JM Evidence-based approach to the medical management of trigeminal neuralgia. Br J Neurosurg. 2007 ; 21: 253-261. (Pubitemid 47035249)
12. Moulin DE, Clark AJ, Gilron I., et al. Canadian Pain Society. Pharmacological management of chronic neuropathic pain- consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007 ; 12: 13-21. (Pubitemid 46744774)
13. Tassone DM, Boyce E., Guyer J., Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 ; 29: 26-48. (Pubitemid 46415802)
14. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol. 2007 ; 20: 456-472. (Pubitemid 47415136)
15. Guay DR Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin ? Am J Geriatr Pharmacother. 2005 ; 3: 274-287. (Pubitemid 43264606)
16. Obermann M., Yoon MS, Sensen K., Maschke M., Diener HC, Katsarava Z. Efficacy of pregabalin in the treatment of trigeminal neuralgia. Cephalalgia. 2008 ; 28: 174-181.
17. Navarro A., Saldaña MT, Pérez C., Masramon X., Rejas J. Health, non-health resources utilization and costs of treating refractory peripheral neuropathic pain (NeP) in primary care setting (PCS) under routine medical practice in Spain [abstract]. Value Health. 2007 ; 10: A465.
18. Perez C., Galvez R., Huelbes S., et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007 ; 5: 66.
19. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987 ; 30: 191-197. (Pubitemid 18029372)
20. Catiálogo de Especialidades Farmacéuticas 2006. Madrid, Spain: Consejo General de Colegios Oficiales de Farmacéuticos ; 2006.
21. Oblikue Consulting, 2006. Base de datos de costes sanitarios. http://www.oblikue.com/bddcostes/. Accessed November 15, 2006.
22. Stewart WF, Ricci JA, Chee E., Morganstein D., Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003 ; 290: 2443-2454. (Pubitemid 37430544)
23. van Leeuwen MT, Blyth FM, March LM, Nicholas MK, Cousins MJ Chronic pain and reduced work effectiveness: the hidden cost to Australian employers. Eur J Pain. 2006 ; 10: 161-166.